Nicole Gaudelli, a co-inventor of base editing, has joined GV Ventures as an entrepreneur-in-residence. Her breakthrough in gene editing has the potential to cure rare diseases caused by point mutations. She hopes to translate her technology into patient treatments and is currently involved in clinical trials for sickle cell disease and alpha-1 antitrypsin deficiency. GV Ventures, impressed with her work, sees great potential in her base editor and supports her innovative endeavors. In a separate development, eGenesis, a startup, has successfully conducted the world's first genetically modified pig kidney transplant into a human. The company plans to expand this technology to hearts and livers, potentially addressing the organ shortage crisis. Additionally, there have been notable developments in various healthcare sectors, such as drug approvals, organ transplantation, and mental health solutions.